IL154984A0 - Estrogen receptor modulators - Google Patents
Estrogen receptor modulatorsInfo
- Publication number
- IL154984A0 IL154984A0 IL15498401A IL15498401A IL154984A0 IL 154984 A0 IL154984 A0 IL 154984A0 IL 15498401 A IL15498401 A IL 15498401A IL 15498401 A IL15498401 A IL 15498401A IL 154984 A0 IL154984 A0 IL 154984A0
- Authority
- IL
- Israel
- Prior art keywords
- estrogen receptor
- receptor modulators
- modulators
- estrogen
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/08—Six-membered rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24158200P | 2000-10-19 | 2000-10-19 | |
| PCT/US2001/042735 WO2002032377A2 (en) | 2000-10-19 | 2001-10-15 | Estrogen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL154984A0 true IL154984A0 (en) | 2003-10-31 |
Family
ID=22911282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15498401A IL154984A0 (en) | 2000-10-19 | 2001-10-15 | Estrogen receptor modulators |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1333827A2 (en) |
| JP (1) | JP2004511502A (en) |
| KR (1) | KR20030042020A (en) |
| CN (1) | CN1469743A (en) |
| AU (2) | AU3238102A (en) |
| BG (1) | BG107676A (en) |
| BR (1) | BR0114689A (en) |
| CA (1) | CA2424729A1 (en) |
| EA (1) | EA200300474A1 (en) |
| EC (1) | ECSP034558A (en) |
| EE (1) | EE200300153A (en) |
| HU (1) | HUP0303563A2 (en) |
| IL (1) | IL154984A0 (en) |
| IS (1) | IS6761A (en) |
| MX (1) | MXPA03003485A (en) |
| NO (1) | NO20031737L (en) |
| PE (1) | PE20021083A1 (en) |
| PL (1) | PL361053A1 (en) |
| SK (1) | SK4772003A3 (en) |
| WO (1) | WO2002032377A2 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030225132A1 (en) * | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
| ATE481397T1 (en) * | 2002-04-24 | 2010-10-15 | Merck Sharp & Dohme | MODULATORS OF THE ESTROGEN RECEPTOR |
| JP4500689B2 (en) * | 2002-12-26 | 2010-07-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Selective estrogen receptor modulator |
| NZ566180A (en) * | 2005-07-29 | 2011-04-29 | Resverlogix Corp | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| EP1944301A4 (en) * | 2005-10-27 | 2012-01-04 | Msd Kk | Novel benzoxathiin derivative |
| PT2118074E (en) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular diseases |
| WO2010079431A2 (en) | 2009-01-08 | 2010-07-15 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| EP2408454A2 (en) | 2009-03-18 | 2012-01-25 | Resverlogix Corp. | Novel anti-inflammatory agents |
| KR101892987B1 (en) | 2009-04-22 | 2018-08-30 | 리스버로직스 코퍼레이션 | Novel anti-inflammatory agents |
| CA2800673A1 (en) | 2010-06-10 | 2011-12-15 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| JP5992049B2 (en) | 2011-11-01 | 2016-09-14 | レスバーロジックス コーポレイション | Oral immediate release formulations for substituted quinazolinones |
| US9187460B2 (en) | 2011-12-14 | 2015-11-17 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| JP2016507496A (en) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | Novel heterocyclic compounds as bromodomain inhibitors |
| CN107530356A (en) | 2015-03-13 | 2018-01-02 | 雷斯韦洛吉克斯公司 | For treating the composition and treatment method of complement-associated disease |
-
2001
- 2001-10-15 EP EP01987654A patent/EP1333827A2/en not_active Withdrawn
- 2001-10-15 HU HU0303563A patent/HUP0303563A2/en unknown
- 2001-10-15 PL PL01361053A patent/PL361053A1/en not_active Application Discontinuation
- 2001-10-15 KR KR10-2003-7005518A patent/KR20030042020A/en not_active Application Discontinuation
- 2001-10-15 MX MXPA03003485A patent/MXPA03003485A/en unknown
- 2001-10-15 EE EEP200300153A patent/EE200300153A/en unknown
- 2001-10-15 AU AU3238102A patent/AU3238102A/en active Pending
- 2001-10-15 JP JP2002535616A patent/JP2004511502A/en not_active Withdrawn
- 2001-10-15 WO PCT/US2001/042735 patent/WO2002032377A2/en not_active Application Discontinuation
- 2001-10-15 EA EA200300474A patent/EA200300474A1/en unknown
- 2001-10-15 SK SK477-2003A patent/SK4772003A3/en unknown
- 2001-10-15 BR BR0114689-0A patent/BR0114689A/en not_active Application Discontinuation
- 2001-10-15 IL IL15498401A patent/IL154984A0/en unknown
- 2001-10-15 AU AU2002232381A patent/AU2002232381B2/en not_active Ceased
- 2001-10-15 CN CNA018176720A patent/CN1469743A/en active Pending
- 2001-10-15 CA CA002424729A patent/CA2424729A1/en not_active Abandoned
-
2002
- 2002-04-15 PE PE2002000308A patent/PE20021083A1/en not_active Application Discontinuation
-
2003
- 2003-03-26 BG BG107676A patent/BG107676A/en unknown
- 2003-03-27 IS IS6761A patent/IS6761A/en unknown
- 2003-04-15 NO NO20031737A patent/NO20031737L/en unknown
- 2003-04-17 EC EC2003004558A patent/ECSP034558A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200300474A1 (en) | 2003-10-30 |
| NO20031737D0 (en) | 2003-04-15 |
| WO2002032377A2 (en) | 2002-04-25 |
| BG107676A (en) | 2003-11-28 |
| NO20031737L (en) | 2003-06-19 |
| CN1469743A (en) | 2004-01-21 |
| EE200300153A (en) | 2003-06-16 |
| AU3238102A (en) | 2002-04-29 |
| CA2424729A1 (en) | 2002-04-25 |
| HUP0303563A2 (en) | 2004-03-01 |
| MXPA03003485A (en) | 2003-07-14 |
| WO2002032377A3 (en) | 2002-08-22 |
| EP1333827A2 (en) | 2003-08-13 |
| ECSP034558A (en) | 2003-06-25 |
| KR20030042020A (en) | 2003-05-27 |
| JP2004511502A (en) | 2004-04-15 |
| PL361053A1 (en) | 2004-09-20 |
| BR0114689A (en) | 2003-07-01 |
| PE20021083A1 (en) | 2002-12-16 |
| AU2002232381B2 (en) | 2004-11-18 |
| IS6761A (en) | 2003-03-27 |
| SK4772003A3 (en) | 2003-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL374215A1 (en) | Selective estrogen receptor modulators | |
| EG25606A (en) | Glucocorticoid receptor modulators | |
| IL150912A0 (en) | Adenosine receptor modulators | |
| EP1200581A4 (en) | Truncated egf receptor | |
| EP1418900A4 (en) | Selective estrogen receptor modulators | |
| IL154984A0 (en) | Estrogen receptor modulators | |
| HK1068875A1 (en) | Tetracyclic heterocompounds as estrogen receptor modulators | |
| IL146151A0 (en) | Human-g-protein receptor | |
| GB0000474D0 (en) | Receptor | |
| AU1252102A (en) | Receptor | |
| AUPQ563400A0 (en) | Novel receptor | |
| GB9913649D0 (en) | Estrogen receptor | |
| HUP0101874A3 (en) | Enzymatic resolution of selective estrogen receptor modulators | |
| GB0100301D0 (en) | Estrogen receptor | |
| GB0100299D0 (en) | Estrogen receptor | |
| GB0100298D0 (en) | Estrogen receptor | |
| AU2002252533A1 (en) | Estrogen receptor modulators | |
| SI1467998T1 (en) | Tetracyclic heterocompounds as estrogen receptor modulators | |
| GB0016230D0 (en) | Estrogen receptors | |
| GB0031096D0 (en) | Receptor | |
| GB0009269D0 (en) | Receptor | |
| GB0014761D0 (en) | Receptor | |
| GB9806032D0 (en) | Estrogen receptor | |
| AU2002249971A1 (en) | Piperazinyltriazines as estrogen receptor modulators | |
| AUPQ915300A0 (en) | Receptor |